Is Eli Lilly using ‘granfluencers’ to raise awareness of its Alzheimer’s med?
By
Marc Iskowitz
Sep 04, 2024
Here’s why older internet celebs — granfluencers — soon might be making rounds on the Alzheimer’s drug marketing scene.
Psychological well-being declines years before diagnosis of MCI
Aug 20, 2024
The findings were seen specifically for the components of purpose in life and personal growth.
What happens if biomarker tests spot Alzheimer’s before people show symptoms?
By
Kristen Fischer
Aug 05, 2024
As of now, no therapy is approved by the Food and Drug Administration for people at risk of Alzheimer’s disease who don’t have symptoms. But blood tests that can spot biomarkers linked to the disease...
Lutheran Senior Services opens Netherlands-inspired dementia village, with more on the way
By
Kimberly Bonvissuto
Jul 30, 2024
Inspired by a dementia village model in the Netherlands, a US senior living operator is opening a new memory care neighborhood concept in two of its communities to provide a “safe and immersive” experience...
New practices, strategies help improve life for those with dementia, caregivers: report
By
Kimberly Bonvissuto
Jul 26, 2024
New practices and strategies are helping senior living communities improve the everyday lives of residents living with dementia and their caregivers, according to a new report from Sodexo that aims to...
Communities break fundraising record during The Longest Day
By
Foster Stubbs
Jul 24, 2024
63 Charter Senior Living communities across the nation raised money for Alzheimer’s research as part of the Alzheimer’s Association’s The Longest Day initiative. Find out more, and learn how to submit...
Senior living providers embrace role in CMS dementia care pilot program
By
Kimberly Bonvissuto
Jul 11, 2024
Senior living providers named participants in the federal government’s new dementia care pilot program said they are excited to be part of a new effort to support people living with dementia and their...
FDA approves new drug to treat Alzheimer’s
Jul 02, 2024
In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
Assisted living will help shape Louisiana’s dementia response plans
By
Kimberly Bonvissuto
Jun 06, 2024
Legislative action creating a coordinated response to Alzheimer’s and dementia in Louisiana is being called a “commendable” step toward addressing the needs of those affected by the disease. And...